scholarly journals Antisense agent reduces LDL–cholesterol levels in high-risk patients

2010 ◽  
Vol 9 (1) ◽  
pp. 10-10
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients ◽  
Antisense Agent

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab

2016 ◽  
Vol 12 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Chanukya Dahagam ◽  
Aditya Goud ◽  
Abdelhai Abdelqader ◽  
Aditya Hendrani ◽  
Matthew J Feinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab

2016 ◽  
Vol 12 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Chanukya Dahagam ◽  
Aditya Goud ◽  
Abdelhai Abdelqader ◽  
Aditya Hendrani ◽  
Matthew J Feinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

Drugs ◽  
2013 ◽  
Vol 73 (4) ◽  
pp. 293-301 ◽  
Author(s):  
Joost Besseling ◽  
Julian van Capelleveen ◽  
John J. P. Kastelein ◽  
G. Kees Hovingh
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Risk Patients ◽  
Low Do

Abstract 18396: Low Rate of LDL-Goal-Attainment in 57,855 High-Risk-Patients in Europe, Canada, South-Africa, Middle East and China - Results of DYSIS

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Anselm K Gitt ◽  
Dominik Lautsch ◽  
Martin Horack ◽  
Baishali Ambegaonkar ◽  
Jean Ferrieres ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Secondary Prevention ◽  
Goal Attainment ◽  
Ldl Cholesterol ◽  
Statin Treatment ◽  
Lipid Lowering ◽  
High Risk Patients ◽  
Risk Patients ◽  
Very High

Background: Statin treatment is routinely used for secondary prevention world-wide. Little is known about the prevalence of persistent lipid abnormalities under chronic statin treatment for secondary prevention and possible differences in LDL-Cholesterol (LDL-C) goal attainment in clinical practice between countries in different parts of the world. Methods: Between 2008 and 2012, consecutive statin-treated outpatients were enrolled in 26 countries worldwide, (DYSIS = Dyslipidemia International Study; list of countries in table) to assess LDL-C goal attainment for secondary prevention. European Society of Cardiology recommendations were used to classify patient risk, and to define LDL-cholesterol treatment goals. Data were collected under real life conditions in physicians’ offices and hospital outpatient wards. Results: Serum lipid values of 57,885 consecutive statin-treated outpatients were studied in the context of their cardiovascular risk factors, and the potency and composition of their lipid-lowering treatment. In the very-high risk patients only 21.7% did reach the currently recommended LDL-Chol target <70mg/dl with large differences between the countries varying from 9.2% to 44.3%. In the high-risk population the LDL-Chol target <100mg/dl was achieved in 38.0% oft he patients, varying between 16.6% and 66.7% between countries Conclusion: Despite chronic statin treatment, only 21.7% of the very-high-risk patients reached the current recommended LDL-Chol target <70mg/dl in this large multinational cross-sectional trial, highlighting the persistent large gap between guideline recommendations and clinical practice. Further treatment escalations are necessary to reduce the risk of subsequent cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document